IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 28,750
-500 (-1.71%)
At close: Aug 28, 2025
IntoCell Company Description
IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer.
It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers.
In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs.
The company was founded in 2015 and is based in Daejeon, South Korea.
IntoCell, Inc.
| Country | South Korea |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Tae-Kyo Park |
Contact Details
Address: 101, Sinildong-ro Daejeon South Korea | |
| Phone | 82 4 2716 0083 |
| Website | intocell.com |
Stock Details
| Ticker Symbol | 287840 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tae-Kyo Park | Chief Executive Officer |
| Young-Suk Suh | Chief Financial Officer |